Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $216.00 USD
Change Today -1.38 / -0.63%
Volume 251.3K
PBYI On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:04 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

puma biotechnology inc (PBYI) Snapshot

Open
$217.98
Previous Close
$217.38
Day High
$223.16
Day Low
$214.31
52 Week High
08/26/14 - $279.37
52 Week Low
06/4/14 - $53.63
Market Cap
6.9B
Average Volume 10 Days
302.9K
EPS TTM
$-4.72
Shares Outstanding
31.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PUMA BIOTECHNOLOGY INC (PBYI)

puma biotechnology inc (PBYI) Related Businessweek News

No Related Businessweek News Found

puma biotechnology inc (PBYI) Details

Puma Biotechnology, Inc., a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients, non-small cell lung cancer patients, and patients with HER2 mutation-positive solid tumors; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also developing PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

120 Employees
Last Reported Date: 03/2/15
Founded in 2010

puma biotechnology inc (PBYI) Top Compensated Officers

Founder, Chairman of The Board, Chief Executi...
Total Annual Compensation: $806.7K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $366.4K
Senior Vice President of Clinical Research an...
Total Annual Compensation: $433.0K
Compensation as of Fiscal Year 2013.

puma biotechnology inc (PBYI) Key Developments

Puma Biotechnology Initiates Phase II Trial of PB272 in Early Stage HER2-Positive Breast Cancer

Puma Biotechnology, Inc. announced the initiation of a Phase II trial of Puma's investigational drug PB272 (neratinib) for the extended adjuvant treatment of breast cancer. The 70 patient study will be an open label single arm Phase II trial of PB272 monotherapy administered to patients with HER2-positive early stage breast cancer who have previously received adjuvant treatment with trastuzumab. Patients will receive extended adjuvant treatment with neratinib for a period of one year. Patients will receive primary prophylaxis with high dose loperamide (16 mg per day initially) in order to attempt to reduce the neratinib-related diarrhea. The primary endpoint of the trial is reduction in the incidence and severity of diarrhea.

Puma Biotechnology, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Puma Biotechnology, Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported loss from operations of $47.6 million against $16.0 million a year ago. Net loss was $47.5 million or $1.57 per share compared to $15.9 million or $0.56 per share for the same period last year. Non-GAAP adjusted net loss was $31.1 million or $1.03 per share against $12.8 million or $0.45 per share a year ago. Net cash used in operating activities for the fourth quarter of 2014 was $18.5 million. For the year, the company reported loss from operations of $142.3 million against $54.8 million a year ago. Net loss was $142.0 million or $4.73 per share compared to $54.6 million or $1.90 per share for the same period last year. Net cash used in operating activities was $77.2 million compared with $55.0 million for the same period last year. Non-GAAP adjusted net loss was $102.8 million or $3.43 per share against $47.1 million or $1.64 per share a year ago. Net cash used in operating activities for the full year 2014 was $77.2 million.

Puma Biotechnology, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015

Puma Biotechnology, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 . Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PBYI:US $216.00 USD -1.38

PBYI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PBYI.
View Industry Companies
 

Industry Analysis

PBYI

Industry Average

Valuation PBYI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 56.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PUMA BIOTECHNOLOGY INC, please visit www.pumabiotechnology.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.